Genome editing of food-grade lactobacilli to develop therapeutic probiotics

Microbiology Spectrum

Volumn 5, Issue 5, 2017, Pages

  Van Pijkeren, Jan Peter ^a   Barrangou, Rodolphe ^b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROBIOTIC AGENT;

ANIMAL; BACTERIAL GENOME; BACTERIAL INFECTION; CHEMISTRY; GENE EDITING; GENETICS; HUMAN; LACTOBACILLUS; PHYSIOLOGY;

ANIMALS; BACTERIAL INFECTIONS; GENE EDITING; GENOME, BACTERIAL; HUMANS; LACTOBACILLUS; PROBIOTICS;

EID: 85030870522     PISSN: None     EISSN: 21650497     Source Type: Journal    
DOI: 10.1128/microbiolspec.BAD-0013-2016     Document Type: Article

References (156)

1. Evershed RP, Payne S, Sherratt AG, Copley MS, Coolidge J, Urem-Kotsu D, Kotsakis K, Ozdoğan M, Ozdoğan AE, Nieuwenhuyse O, Akkermans PMMG, Bailey D, Andeescu R-R, Campbell S, Farid S, Hodder I, Yalman N, Ozbaşaran M, Biçakci E, Garfinkel Y, Levy T, Burton MM. 2008. Earliest date for milk use in the Near East and southeastern Europe linked to cattle herding. Nature 455:528-531. http://dx.doi.org/10.1038/nature07180
2. Salque M, Bogucki PI, Pyzel J, Sobkowiak-Tabaka I, Grygiel R, Szmyt M, Evershed RP. 2013. Earliest evidence for cheese making in the sixth millennium BC in northern Europe. Nature 493:522-525. http://dx.doi.org/10.1038/nature11698
3. Das D, Goyal A. 2012. Lactic acid bacteria in food industry, p 757-772. In Microorganisms in Sustainable Agriculture and Biotechnology. Springer Netherlands, Dordrecht, The Netherlands. http://dx.doi.org/10.1007/978-94-007-2214-9_33
4. König H, Fröhlich J. 2009. Lactic acid bacteria, p 3-29. In König H, Fröhlich J, Unden G (ed), Biology of Microorganisms on Grapes, in Must and in Wine. Springer, Heidelberg, Germany. http://dx.doi.org/10.1007/978-3-540-85463-0_1
5. Metchnikoff E. 1910. The Prolongation of Life. Optimistic Studies. G.P. Putnam's Sons, New York, NY.
6. Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, Morelli L, Canani RB, Flint HJ, Salminen S, Calder PC, Sanders ME. 2014. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol 11:506-514. http://dx.doi.org/10.1038/nrgastro.2014.66
7. Kulp WL, Rettger LF. 1924. Comparative study of Lactobacillus acidophilus and Lactobacillus bulgaricus. J Bacteriol 9:357-395.
8. Elli M, Callegari ML, Ferrari S, Bessi E, Cattivelli D, Soldi S, Morelli L, Goupil Feuillerat N, Antoine JM. 2006. Survival of yogurt bacteria in the human gut. Appl Environ Microbiol 72:5113-5117. http://dx.doi.org/10.1128/AEM.02950-05
9. Steidler L, Hans W, Schotte L, Neirynck S, Obermeier F, Falk W, Fiers W, Remaut E. 2000. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 289:1352-1355. http://dx.doi.org/10.1126/science.289.5483.1352
10. Bahey-El-Din M, Gahan CGM, Griffin BT. 2010. Lactococcus lactis as a cell factory for delivery of therapeutic proteins. Curr Gene Ther 10:34-45. http://dx.doi.org/10.2174/156652310790945557
11. Robert S, Steidler L. 2014. Recombinant Lactococcus lactis can make the difference in antigen-specific immune tolerance induction, the type 1 diabetes case. Microb Cell Fact 13(Suppl 1):S11. http://dx.doi.org/10.1186/1475-2859-13-S1-S11
12. Guimarães V, Innocentin S, Chatel J-M, Lefèvre F, Langella P, Azevedo V, Miyoshi A. 2009. A new plasmid vector for DNA delivery using lactococci. Genet Vaccines Ther 7:4. http://dx.doi.org/10.1186/1479-0556-7-4
13. Chatel J-M, Pothelune L, Ah-Leung S, Corthier G, Wal J-M, Langella P. 2008. In vivo transfer of plasmid from food-grade transiting lactococci to murine epithelial cells. Gene Ther 15:1184-1190. http://dx.doi.org/10.1038/gt.2008.59
14. de Azevedo M, Karczewski J, Lefévre F, Azevedo V, Miyoshi A, Wells JM, Langella P, Chatel J-M. 2012. In vitro and in vivo characterization of DNA delivery using recombinant Lactococcus lactis expressing a mutated form of L. monocytogenes internalin A. BMC Microbiol 12:299. http://dx.doi.org/10.1186/1471-2180-12-299
15. Cavanagh D, Fitzgerald GF, McAuliffe O. 2015. From field to fermentation:the origins of Lactococcus lactis and its domestication to the dairy environment. Food Microbiol 47:45-61. http://dx.doi.org/10.1016/j.fm.2014.11.001
16. Daniel C, Poiret S, Dennin V, Boutillier D, Pot B. 2013. Bioluminescence imaging study of spatial and temporal persistence of Lactobacillus plantarum and Lactococcus lactis in living mice. Appl Environ Microbiol 79:1086-1094. http://dx.doi.org/10.1128/AEM.03221-12
17. Vesa T, Pochart P, Marteau P. 2000. Pharmacokinetics of Lactobacillus plantarum NCIMB 8826, Lactobacillus fermentum KLD, and Lactococcus lactis MG 1363 in the human gastrointestinal tract. Aliment Pharmacol Ther 14:823-828. http://dx.doi.org/10.1046/j.1365-2036.2000.00763.x
18. Ou B, Yang Y, Tham WL, Chen L, Guo J, Zhu G. 2016. Genetic engineering of probiotic Escherichia coli Nissle 1917 for clinical application. Appl Microbiol Biotechnol 100:8693-8699. http://dx.doi.org/10.1007/s00253-016-7829-5
19. Sonnenborn U. 2016. Escherichia coli strain Nissle 1917-from bench to bedside and back: history of a special Escherichia coli strain with probiotic properties. FEMS Microbiol Lett 363:fnw212. http://dx.doi.org/10.1093/femsle/fnw212
20. Wassenaar TM. 2016. Insights from 100 years of research with probiotic E. coli. Eur J Microbiol Immunol (Bp) 6:147-161. http://dx.doi.org/10.1556/1886.2016.00029
21. Sun Z, Harris HMB, McCann A, Guo C, Argimón S, Zhang W, Yang X, Jeffery IB, Cooney JC, Kagawa TF, Liu W, Song Y, Salvetti E, Wrobel A, Rasinkangas P, Parkhill J, Rea MC, O'Sullivan O, Ritari J, Douillard FP, Paul Ross R, Yang R, Briner AE, Felis GE, de Vos WM, Barrangou R, Klaenhammer TR, Caufield PW, Cui Y, Zhang H, O'Toole PW. 2015. Expanding the biotechnology potential of lactobacilli through comparative genomics of 213 strains and associated genera. Nat Commun 6:8322. http://dx.doi.org/10.1038/ncomms9322
22. Giraffa G. 2014. Overview of the ecology and biodiversity of the LAB, p 45-54. In Holzapfel WH, Wood BJB (ed), Lactic Acid Bacteria. John Wiley & Sons, Chichester, United Kingdom. http://dx.doi.org/10.1002/9781118655252.ch4
23. Oozeer R, Leplingard A, Mater DDG, Mogenet A, Michelin R, Seksek I, Marteau P, Doré J, Bresson J-L, Corthier G. 2006. Survival of Lactobacillus casei in the human digestive tract after consumption of fermented milk. Appl Environ Microbiol 72:5615-5617. http://dx.doi.org/10.1128/AEM.00722-06
24. Frese SA, Hutkins RW, Walter J. 2012. Comparison of the colonization ability of autochthonous and allochthonous strains of lactobacilli in the human gastrointestinal tract. Adv Microbiol 2:399-409. http://dx.doi.org/10.4236/aim.2012.23051
25. Pitino I, Randazzo CL, Mandalari G, Lo Curto A, Faulks RM, Le Marc Y, Bisignano C, Caggia C, Wickham MSJ. 2010. Survival of Lactobacillus rhamnosus strains in the upper gastrointestinal tract. Food Microbiol 27:1121-1127. http://dx.doi.org/10.1016/j.fm.2010.07.019
26. de Vries MC, Vaughan EE, Kleerebezem M, de Vos WM. 2006. Lactobacillus plantarum: survival, functional and potential probiotic properties in the human intestinal tract. Int Dairy J 16:1018-1028. http://dx.doi.org/10.1016/j.idairyj.2005.09.003
27. Fux CA, Shirtliff M, Stoodley P, Costerton JW. 2005. Can laboratory reference strains mirror "real-world" pathogenesis? Trends Microbiol 13:58-63. http://dx.doi.org/10.1016/j.tim.2004.11.001
28. Eydallin G, Ryall B, Maharjan R, Ferenci T. 2014. The nature of laboratory domestication changes in freshly isolated Escherichia coli strains. Environ Microbiol 16:813-828. http://dx.doi.org/10.1111/1462-2920.12208
29. Derous V, Deboeck F, Hernalsteens J-P, De Greve H. 2011. Reproducible gene targeting in recalcitrant Escherichia coli isolates. BMC Res Notes 4:213. http://dx.doi.org/10.1186/1756-0500-4-213
30. O'Hara AM, O'Regan P, Fanning A, O'Mahony C, Macsharry J, Lyons A, Bienenstock J, O'Mahony L, Shanahan F. 2006. Functional modulation of human intestinal epithelial cell responses by Bifidobacterium infantis and Lactobacillus salivarius. Immunology 118:202-215. http://dx.doi.org/10.1111/j.1365-2567.2006.02358.x
31. O'Callaghan J, Buttó LF, MacSharry J, Nally K, O'Toole PW. 2012. Influence of adhesion and bacteriocin production by Lactobacillus salivarius on the intestinal epithelial cell transcriptional response. Appl Environ Microbiol 78:5196-5203. http://dx.doi.org/10.1128/AEM.00507-12
32. Ryan KA, O'Hara AM, van Pijkeren J-P, Douillard FP, O'Toole PW. 2009. Lactobacillus salivarius modulates cytokine induction and virulence factor gene expression in Helicobacter pylori. J Med Microbiol 58:996-1005. doi:10.1099/jmm.0.009407-0
33. O'Shea EF, O'Connor PM, Raftis EJ, O'Toole PW, Stanton C, Cotter PD, Ross RP, Hill C. 2011. Production of multiple bacteriocins from a single locus by gastrointestinal strains of Lactobacillus salivarius. J Bacteriol 193:6973-6982. http://dx.doi.org/10.1128/JB.06221-11
34. Miyauchi E, O'Callaghan J, Buttó LF, Hurley G, Melgar S, Tanabe S, Shanahan F, Nally K, O'Toole PW. 2012. Mechanism of protection of transepithelial barrier function by Lactobacillus salivarius: strain dependence and attenuation by bacteriocin production. Am J Physiol Gastrointest Liver Physiol 303:G1029-G1041. http://dx.doi.org/10.1152/ajpgi.00003.2012
35. Corr SC, Li Y, Riedel CU, O'Toole PW, Hill C, Gahan CGM. 2007. Bacteriocin production as a mechanism for the antiinfective activity of Lactobacillus salivarius UCC118. Proc Natl Acad Sci USA 104:7617-7621. http://dx.doi.org/10.1073/pnas.0700440104
36. Collins J, van Pijkeren J-P, Svensson L, Claesson MJ, Sturme M, Li Y, Cooney JC, van Sinderen D, Walker AW, Parkhill J, Shannon O, O'Toole PW. 2012. Fibrinogen-binding and platelet-aggregation activities of a Lactobacillus salivarius septicaemia isolate are mediated by a novel fibrinogen-binding protein. Mol Microbiol 85:862-877. http://dx.doi.org/10.1111/j.1365-2958.2012.08148.x
37. Fitzgerald JR, Foster TJ, Cox D. 2006. The interaction of bacterial pathogens with platelets. Nat Rev Microbiol 4:445-457. http://dx.doi.org/10.1038/nrmicro1425
38. Spinler JK, Taweechotipatr M, Rognerud CL, Ou CN, Tumwasorn S, Versalovic J. 2008. Human-derived probiotic Lactobacillus reuteri demonstrate antimicrobial activities targeting diverse enteric bacterial pathogens. Anaerobe 14:166-171. http://dx.doi.org/10.1016/j.anaerobe.2008.02.001
39. Spinler JK, Sontakke A, Hollister EB, Venable SF, Oh PL, Balderas MA, Saulnier DMA, Mistretta T-A, Devaraj S, Walter J, Versalovic J, Highlander SK. 2014. From prediction to function using evolutionary genomics: human-specific ecotypes of Lactobacillus reuteri have diverse probiotic functions. Genome Biol Evol 6:1772-1789. http://dx.doi.org/10.1093/gbe/evu137
40. Hemarajata P, Gao C, Pflughoeft KJ, Thomas CM, Saulnier DM, Spinler JK, Versalovic J. 2013. Lactobacillus reuteri-specific immunoregulatory gene rsiR modulates histamine production and immunomodulation by Lactobacillus reuteri. J Bacteriol 195:5567-5576. http://dx.doi.org/10.1128/JB.00261-13
41. Thomas CM, Hong T, van Pijkeren J-P, Hemarajata P, Trinh DV, Hu W, Britton RA, Kalkum M, Versalovic J. 2012. Histamine derived from probiotic Lactobacillus reuteri suppresses TNF via modulation of PKA and ERK signaling. PLoS One 7:e31951. http://dx.doi.org/10.1371/journal.pone.0031951
42. Lambert JM, Bongers RS, Kleerebezem M. 2007. Cre-lox-based system for multiple gene deletions and selectable-marker removal in Lactobacillus plantarum. Appl Environ Microbiol 73:1126-1135. http://dx.doi.org/10.1128/AEM.01473-06
43. Auvray F, Coddeville M, Ritzenthaler P, Dupont L. 1997. Plasmid integration in a wide range of bacteria mediated by the integrase of Lactobacillus delbrueckii bacteriophage mv4. J Bacteriol 179:1837-1845. http://dx.doi.org/10.1128/jb.179.6.1837-1845.1997
44. Sasikumar P, Paul E, Gomathi S, Abhishek A, Sasikumar S, Selvam GS. 2016. Mobile group II intron based gene targeting in Lactobacillus plantarum WCFS1. J Basic Microbiol 56:1107-1116. http://dx.doi.org/10.1002/jobm.201500746
45. Russell WM, Klaenhammer TR. 2001. Efficient system for directed integration into the Lactobacillus acidophilus and Lactobacillus gasseri chromosomes via homologous recombination. Appl Environ Microbiol 67:4361-4364. http://dx.doi.org/10.1128/AEM.67.9.4361-4364.2001
46. van Pijkeren J-P, Canchaya C, Ryan KA, Li Y, Claesson MJ, Sheil B, Steidler L, O'Mahony L, Fitzgerald GF, van Sinderen D, O'Toole PW. 2006. Comparative and functional analysis of sortase-dependent proteins in the predicted secretome of Lactobacillus salivarius UCC118. Appl Environ Microbiol 72:4143-4153. http://dx.doi.org/10.1128/AEM.03023-05
47. Goh Y-J, Azcárate-Peril MA, O'Flaherty S, Durmaz E, Valence F, Jardin J, Lortal S, Klaenhammer TR. 2009. Development and application of a upp-based counterselective gene replacement system for the study of the S-layer protein SlpX of Lactobacillus acidophilus NCFM. Appl Environ Microbiol 75:3093-3105. http://dx.doi.org/10.1128/AEM.02502-08
48. van Pijkeren J-P, Britton RA. 2012. High efficiency recombineering in lactic acid bacteria. Nucleic Acids Res 40:e76. http://dx.doi.org/10.1093/nar/gks147
49. van Pijkeren J-P, Britton RA. 2014. Precision genome engineering in lactic acid bacteria. Microb Cell Fact 13(Suppl 1):S10. http://dx.doi.org/10.1186/1475-2859-13-S1-S10
50. Oh J-H, van Pijkeren J-P. 2014. CRISPR-Cas9-assisted recombineering in Lactobacillus reuteri. Nucleic Acids Res 42:e131. http://dx.doi.org/10.1093/nar/gku623
51. Makarova KS, Wolf YI, Alkhnbashi OS, Costa F, Shah SA, Saunders SJ, Barrangou R, Brouns SJJ, Charpentier E, Haft DH, Horvath P, Moineau S, Mojica FJM, Terns RM, Terns MP, White MF, Yakunin AF, Garrett RA, van der Oost J, Backofen R, Koonin EV. 2015. An updated evolutionary classification of CRISPR-Cas systems. Nat Rev Microbiol 13:722-736. http://dx.doi.org/10.1038/nrmicro3569
52. Barrangou R, Fremaux C, Deveau H, Richards M, Boyaval P, Moineau S, Romero DA, Horvath P. 2007. CRISPR provides acquired resistance against viruses in prokaryotes. Science 315:1709-1712. http://dx.doi.org/10.1126/science.1138140
53. Brouns SJJ, Jore MM, Lundgren M, Westra ER, Slijkhuis RJH, Snijders APL, Dickman MJ, Makarova KS, Koonin EV, van der Oost J. 2008. Small CRISPR RNAs guide antiviral defense in prokaryotes. Science 321:960-964. http://dx.doi.org/10.1126/science.1159689
54. Marraffini LA, Sontheimer EJ. 2010. CRISPR interference: RNAdirected adaptive immunity in bacteria and archaea. Nat Rev Genet 11:181-190. http://dx.doi.org/10.1038/nrg2749
55. Garneau JE, Dupuis M-È, Villion M, Romero DA, Barrangou R, Boyaval P, Fremaux C, Horvath P, Magadán AH, Moineau S. 2010. The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA. Nature 468:67-71. http://dx.doi.org/10.1038/nature09523
56. Gasiunas G, Barrangou R, Horvath P, Siksnys V. 2012. Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. Proc Natl Acad Sci USA 109:E2579-E2586. http://dx.doi.org/10.1073/pnas.1208507109
57. Barrangou R. 2015. Diversity of CRISPR-Cas immune systems and molecular machines. Genome Biol 16:247. http://dx.doi.org/10.1186/s13059-015-0816-9
58. Deltcheva E, Chylinski K, Sharma CM, Gonzales K, Chao Y, Pirzada ZA, Eckert MR, Vogel J, Charpentier E. 2011. CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III. Nature 471:602-607. http://dx.doi.org/10.1038/nature09886
59. Pennisi E. 2013. The CRISPR craze. Science 341:833-836. http://dx.doi.org/10.1126/science.341.6148.833
60. Hilton IB, D'Ippolito AM, Vockley CM, Thakore PI, Crawford GE, Reddy TE, Gersbach CA. 2015. Epigenome editing by a CRISPR-Cas9- based acetyltransferase activates genes from promoters and enhancers. Nat Biotechnol 33:510-517. http://dx.doi.org/10.1038/nbt.3199
61. Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, Norville JE, Church GM. 2013. RNA-guided human genome engineering via Cas9. Science 339:823-826. http://dx.doi.org/10.1126/science.1232033
62. Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, Hsu PD, Wu X, Jiang W, Marraffini LA, Zhang F. 2013. Multiplex genome engineering using CRISPR/Cas systems. Science 339:819-823. http://dx.doi.org/10.1126/science.1231143
63. Selle K, Barrangou R. 2015. Harnessing CRISPR-Cas systems for bacterial genome editing. Trends Microbiol 23:225-232. http://dx.doi.org/10.1016/j.tim.2015.01.008
64. Barrangou R, Marraffini LA. 2014. CRISPR-Cas systems: prokaryotes upgrade to adaptive immunity. Mol Cell 54:234-244. http://dx.doi.org/10.1016/j.molcel.2014.03.011
65. Sontheimer EJ, Barrangou R. 2015. The bacterial origins of the CRISPR genome-editing revolution. Hum Gene Ther 26:413-424. http://dx.doi.org/10.1089/hum.2015.091
66. Hsu PD, Lander ES, Zhang F. 2014. Development and applications of CRISPR-Cas9 for genome engineering. Cell 157:1262-1278. http://dx.doi.org/10.1016/j.cell.2014.05.010
67. Sander JD, Joung JK. 2014. CRISPR-Cas systems for editing, regulating and targeting genomes. Nat Biotechnol 32:347-355. http://dx.doi.org/10.1038/nbt.2842
68. Makarova K, Slesarev A, Wolf Y, Sorokin A, Mirkin B, Koonin E, Pavlov A, Pavlova N, Karamychev V, Polouchine N, Shakhova V, Grigoriev I, Lou Y, Rohksar D, Lucas S, Huang K, Goodstein DM, Hawkins T, Plengvidhya V, Welker D, Hughes J, Goh Y, Benson A, Baldwin K, Lee J-H, Díaz-Muñiz I, Dosti B, Smeianov V, Wechter W, Barabote R, Lorca G, Altermann E, Barrangou R, Ganesan B, Xie Y, Rawsthorne H, Tamir D, Parker C, Breidt F, Broadbent J, Hutkins R, O'Sullivan D, Steele J, Unlu G, Saier M, Klaenhammer T, Richardson P, Kozyavkin S, Weimer B, Mills D. 2006. Comparative genomics of the lactic acid bacteria. Proc Natl Acad Sci USA 103:15611-15616. http://dx.doi.org/10.1073/pnas.0607117103
69. Canchaya C, Claesson MJ, Fitzgerald GF, van Sinderen D, O'Toole PW. 2006. Diversity of the genus Lactobacillus revealed by comparative genomics of five species. Microbiology 152:3185-3196. http://dx.doi.org/10.1099/mic.0.29140-0
70. Selle K, Klaenhammer TR, Barrangou R. 2015. CRISPR-based screening of genomic island excision events in bacteria. Proc Natl Acad Sci USA 112:8076-8081. http://dx.doi.org/10.1073/pnas.1508525112
71. Barrangou R, van Pijkeren J-P. 2016. Exploiting CRISPR-Cas immune systems for genome editing in bacteria. Curr Opin Biotechnol 37:61-68. http://dx.doi.org/10.1016/j.copbio.2015.10.003
72. Kleerebezem M, Hols P, Bernard E, Rolain T, Zhou M, Siezen RJ, Bron PA. 2010. The extracellular biology of the lactobacilli. FEMS Microbiol Rev 34:199-230. http://dx.doi.org/10.1111/j.1574-6976.2009.00208.x
73. Brown L, Wolf JM, Prados-Rosales R, Casadevall A. 2015. Through the wall: extracellular vesicles in Gram-positive bacteria, mycobacteria and fungi. Nat Rev Microbiol 13:620-630. http://dx.doi.org/10.1038/nrmicro3480
74. Brown S, Santa Maria JP Jr, Walker S. 2013. Wall teichoic acids of Gram-positive bacteria. Annu Rev Microbiol 67:313-336. http://dx.doi.org/10.1146/annurev-micro-092412-155620
75. Chapot-Chartier M-P, Kulakauskas S. 2014. Cell wall structure and function in lactic acid bacteria. Microb Cell Fact 13(Suppl 1):S9. http://dx.doi.org/10.1186/1475-2859-13-S1-S9
76. Matsuguchi T, Takagi A, Matsuzaki T, Nagaoka M, Ishikawa K, Yokokura T, Yoshikai Y. 2003. Lipoteichoic acids from Lactobacillus strains elicit strong tumor necrosis factor alpha-inducing activities in macrophages through Toll-like receptor 2. Clin Diagn Lab Immunol 10:259-266.
77. Dessing MC, Schouten M, Draing C, Levi M, von Aulock S, van der Poll T. 2008. Role played by Toll-like receptors 2 and 4 in lipoteichoic acid-induced lung inflammation and coagulation. J Infect Dis 197:245-252. http://dx.doi.org/10.1086/524873
78. Walter J, Loach DM, Alqumber M, Rockel C, Hermann C, Pfitzenmaier M, Tannock GW. 2007. D-alanyl ester depletion of teichoic acids in Lactobacillus reuteri 100-23 results in impaired colonization of the mouse gastrointestinal tract. Environ Microbiol 9:1750-1760. http://dx.doi.org/10.1111/j.1462-2920.2007.01292.x
79. Grangette C, Nutten S, Palumbo E, Morath S, Hermann C, Dewulf J, Pot B, Hartung T, Hols P, Mercenier A. 2005. Enhanced antiinflammatory capacity of a Lactobacillus plantarum mutant synthesizing modified teichoic acids. Proc Natl Acad Sci USA 102:10321-10326. http://dx.doi.org/10.1073/pnas.0504084102
80. Kaji R, Kiyoshima-Shibata J, Nagaoka M, Nanno M, Shida K. 2010. Bacterial teichoic acids reverse predominant IL-12 production induced by certain Lactobacillus strains into predominant IL-10 production via TLR2-dependent ERK activation in macrophages. J Immunol 184:3505-3513. http://dx.doi.org/10.4049/jimmunol.0901569
81. Duncker SC, Wang L, Hols P, Bienenstock J. 2008. The D-alanine content of lipoteichoic acid is crucial for Lactobacillus plantarummediated protection from visceral pain perception in a rat colorectal distension model. Neurogastroenterol Motil 20:843-850. http://dx.doi.org/10.1111/j.1365-2982.2008.01085.x
82. Smelt MJ, de Haan BJ, Bron PA, van Swam I, Meijerink M, Wells JM, Kleerebezem M, Faas MM, de Vos P. 2013. The impact of Lactobacillus plantarum WCFS1 teichoic acid D-alanylation on the generation of effector and regulatory T-cells in healthy mice. PLoS One 8:e63099. http://dx.doi.org/10.1371/journal.pone.0063099
83. Korhonen R, Kosonen O, Korpela R, Moilanen E. 2004. The expression of COX2 protein induced by Lactobacillus rhamnosus GG, endotoxin and lipoteichoic acid in T84 epithelial cells. Lett Appl Microbiol 39:19-24. http://dx.doi.org/10.1111/j.1472-765X.2004.01531.x
84. Khazaie K, Zadeh M, Khan MW, Bere P, Gounari F, Dennis K, Blatner NR, Owen JL, Klaenhammer TR, Mohamadzadeh M. 2012. Abating colon cancer polyposis by Lactobacillus acidophilus deficient in lipoteichoic acid. Proc Natl Acad Sci USA 109:10462-10467. http://dx.doi.org/10.1073/pnas.1207230109
85. Law J, Buist G, Haandrikman A, Kok J, Venema G, Leenhouts K. 1995. A system to generate chromosomal mutations in Lactococcus lactis which allows fast analysis of targeted genes. J Bacteriol 177:7011-7018. http://dx.doi.org/10.1128/jb.177.24.7011-7018.1995
86. Bron PA, Tomita S, Mercenier A, Kleerebezem M. 2013. Cell surface-associated compounds of probiotic lactobacilli sustain the strainspecificity dogma. Curr Opin Microbiol 16:262-269. http://dx.doi.org/10.1016/j.mib.2013.06.001
87. Lebeer S, Vanderleyden J, De Keersmaecker SCJ. 2010. Host interactions of probiotic bacterial surface molecules: comparison with commensals and pathogens. Nat Rev Microbiol 8:171-184. http://dx.doi.org/10.1038/nrmicro2297
88. Lebeer S, Vanderleyden J, De Keersmaecker SCJ. 2008. Genes and molecules of lactobacilli supporting probiotic action. Microbiol Mol Biol Rev 72:728-764. http://dx.doi.org/10.1128/MMBR.00017-08
89. Faith JJ, McNulty NP, Rey FE, Gordon JI. 2011. Predicting a human gut microbiota's response to diet in gnotobiotic mice. Science 333:101-104. http://dx.doi.org/10.1126/science.1206025
90. McNulty NP, Yatsunenko T, Hsiao A, Faith JJ, Muegge BD, Goodman AL, Henrissat B, Oozeer R, Cools-Portier S, Gobert G, Chervaux C, Knights D, Lozupone CA, Knight R, Duncan AE, Bain JR, Muehlbauer MJ, Newgard CB, Heath AC, Gordon JI. 2011. The impact of a consortium of fermented milk strains on the gut microbiome of gnotobiotic mice and monozygotic twins. Sci Trans Med 3:106ra106.
91. García-Fruitós E. 2012. Lactic acid bacteria: a promising alternative for recombinant protein production. Microb Cell Fact 11:157. http://dx.doi.org/10.1186/1475-2859-11-157
92. Rodríguez JM, Martínez MI, Horn N, Dodd HM. 2003. Heterologous production of bacteriocins by lactic acid bacteria. Int J Food Microbiol 80:101-116. http://dx.doi.org/10.1016/S0168-1605(02)00153-8
93. de Ruyter PG, Kuipers OP, de Vos WM. 1996. Controlled gene expression systems for Lactococcus lactis with the food-grade inducer nisin. Appl Environ Microbiol 62:3662-3667.
94. LeBlanc JG, Aubry C, Cortes-Perez NG, de Moreno de LeBlanc A, Vergnolle N, Langella P, Azevedo V, Chatel J-M, Miyoshi A, Bermúdez-Humarán LG. 2013. Mucosal targeting of therapeutic molecules using genetically modified lactic acid bacteria: an update. FEMS Microbiol Lett 344:1-9. http://dx.doi.org/10.1111/1574-6968.12159
95. Repa A, Grangette C, Daniel C, Hochreiter R, Hoffmann-Sommergruber K, Thalhamer J, Kraft D, Breiteneder H, Mercenier A, Wiedermann U. 2003. Mucosal co-application of lactic acid bacteria and allergen induces counter-regulatory immune responses in a murine model of birch pollen allergy. Vaccine 22:87-95. http://dx.doi.org/10.1016/S0264-410X(03)00528-0
96. Round JL, Mazmanian SK. 2009. The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol 9:313-323. http://dx.doi.org/10.1038/nri2515
97. Ianiro G, Tilg H, Gasbarrini A. 2016. Antibiotics as deep modulators of gut microbiota: between good and evil. Gut 65:gutjnl-2016-312297. doi:10.1136/gutjnl-2016-312297.
98. Cox LM, Blaser MJ. 2015. Antibiotics in early life and obesity. Nat Rev Endocrinol 11:182-190. http://dx.doi.org/10.1038/nrendo.2014.210
99. Russell SL, Gold MJ, Hartmann M, Willing BP, Thorson L, Wlodarska M, Gill N, Blanchet M-R, Mohn WW, McNagny KM, Finlay BB. 2012. Early life antibiotic-driven changes in microbiota enhance susceptibility to allergic asthma. EMBO Rep 13:440-447. http://dx.doi.org/10.1038/embor.2012.32
100. Slimings C, Riley TV. 2014. Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and metaanalysis. J Antimicrob Chemother 69:881-891. http://dx.doi.org/10.1093/jac/dkt477
101. World Health Organization. 2014. Antimicrobial Resistance: Global Report on Surveillance. World Health Organization, Geneva Switzerland.
102. Lewis K. 2013. Platforms for antibiotic discovery. Nat Rev Drug Discov 12:371-387. http://dx.doi.org/10.1038/nrd3975
103. Villa TG, Veiga-Crespo P (ed). 2009. Enzybiotics: Antibiotic Enzymes as Drugs and Therapeutics. John Wiley & Sons, Inc, Hoboken, NJ.
104. Alvarez-Sieiro P, Montalbán-López M, Mu D, Kuipers OP. 2016. Bacteriocins of lactic acid bacteria: extending the family. Appl Microbiol Biotechnol 100:2939-2951. http://dx.doi.org/10.1007/s00253-016-7343-9
105. Cotter PD, Ross RP, Hill C. 2013. Bacteriocins: a viable alternative to antibiotics? Nat Rev Microbiol 11:95-105. http://dx.doi.org/10.1038/nrmicro2937
106. Riboulet-Bisson E, Sturme MHJ, Jeffery IB, O'Donnell MM, Neville BA, Forde BM, Claesson MJ, Harris H, Gardiner GE, Casey PG, Lawlor PG, O'Toole PW, Ross RP. 2012. Effect of Lactobacillus salivarius bacteriocin Abp118 on the mouse and pig intestinal microbiota. PLoS One 7:e31113. http://dx.doi.org/10.1371/journal.pone.0031113
107. Kommineni S, Bretl DJ, Lam V, Chakraborty R, Hayward M, Simpson P, Cao Y, Bousounis P, Kristich CJ, Salzman NH. 2015. Bacteriocin production augments niche competition by enterococci in the mammalian gastrointestinal tract. Nature 526:719-722. http://dx.doi.org/10.1038/nature15524
108. Field D, Connor PMO, Cotter PD, Hill C, Ross RP. 2008. The generation of nisin variants with enhanced activity against specific Gram-positive pathogens. Mol Microbiol 69:218-230. http://dx.doi.org/10.1111/j.1365-2958.2008.06279.x
109. Field D, Begley M, O'Connor PM, Daly KM, Hugenholtz F, Cotter PD, Hill C, Ross RP. 2012. Bioengineered nisin A derivatives with enhanced activity against both Gram positive and Gram negative pathogens. PLoS One 7:e46884. http://dx.doi.org/10.1371/journal.pone.0046884
110. van Pijkeren J-P, Neoh KM, Sirias D, Findley AS, Britton RA. 2012. Exploring optimization parameters to increase ssDNA recombineering in Lactococcus lactis and Lactobacillus reuteri. Bioengineered 3:209-217. http://dx.doi.org/10.4161/bioe.21049
111. Doleyres Y, Beck P, Vollenweider S, Lacroix C. 2005. Production of 3-hydroxypropionaldehyde using a two-step process with Lactobacillus reuteri. Appl Microbiol Biotechnol 68:467-474. http://dx.doi.org/10.1007/s00253-005-1895-4
112. De Weirdt R, Crabbé A, Roos S, Vollenweider S, Lacroix C, van Pijkeren J-P, Britton RA, Sarker S, Van de Wiele T, Nickerson CA. 2012. Glycerol supplementation enhances L. reuteri's protective effect against S. Typhimurium colonization in a 3-D model of colonic epithelium. PLoS One 7:e37116. http://dx.doi.org/10.1371/journal.pone.0037116
113. Talarico TL, Casas IA, Chung TC, Dobrogosz WJ. 1988. Production and isolation of reuterin, a growth inhibitor produced by Lactobacillus reuteri. Antimicrob Agents Chemother 32:1854-1858. http://dx.doi.org/10.1128/AAC.32.12.1854
114. Dishisha T, Pereyra LP, Pyo S-H, Britton RA, Hatti-Kaul R. 2014. Flux analysis of the Lactobacillus reuteri propanediol-utilization pathway for production of 3-hydroxypropionaldehyde, 3-hydroxypropionic acid and 1,3-propanediol from glycerol. Microb Cell Fact 13:76. http://dx.doi.org/10.1186/1475-2859-13-76
115. Schaefer L, Auchtung TA, Hermans KE, Whitehead D, Borhan B, Britton RA. 2010. The antimicrobial compound reuterin (3- hydroxypropionaldehyde) induces oxidative stress via interaction with thiol groups. Microbiology 156:1589-1599. http://dx.doi.org/10.1099/mic.0.035642-0
116. Rakonjac J, Bennett NJ, Spagnuolo J, Gagic D, Russel M. 2011. Filamentous bacteriophage: biology, phage display and nanotechnology applications. Curr Issues Mol Biol 13:51-76.
117. Rakonjac J, Feng J, Model P. 1999. Filamentous phage are released from the bacterial membrane by a two-step mechanism involving a short C-terminal fragment of pIII. J Mol Biol 289:1253-1265. http://dx.doi.org/10.1006/jmbi.1999.2851
118. Sheehan MM, Stanley E, Fitzgerald GF, van Sinderen D. 1999. Identification and characterization of a lysis module present in a large proportion of bacteriophages infecting Streptococcus thermophilus. Appl Environ Microbiol 65:569-577.
119. Wang IN, Smith DL, Young R. 2000. Holins: the protein clocks of bacteriophage infections. Annu Rev Microbiol 54:799-825. http://dx.doi.org/10.1146/annurev.micro.54.1.799
120. Fischetti VA. 2009. Bacteriophage Lysins: The Ultimate Enzybiotic. John Wiley & Sons, Inc, Hoboken, NJ.
121. Cheng X, Zhang X, Pflugrath JW, Studier FW. 1994. The structure of bacteriophage T7 lysozyme, a zinc amidase and an inhibitor of T7 RNA polymerase. Proc Natl Acad Sci USA 91:4034-4038. http://dx.doi.org/10.1073/pnas.91.9.4034
122. Nelson D, Schuch R, Chahales P, Zhu S, Fischetti VA. 2006. PlyC:a multimeric bacteriophage lysin. Proc Natl Acad Sci USA 103:10765-10770. http://dx.doi.org/10.1073/pnas.0604521103
123. Navarre WW, Ton-That H, Faull KF, Schneewind O. 1999. Multiple enzymatic activities of the murein hydrolase from staphylococcal phage φ11. Identification of a D-alanyl-glycine endopeptidase activity. J Biol Chem 274:15847-15856. http://dx.doi.org/10.1074/jbc.274.22.15847
124. Becker SC, Dong S, Baker JR, Foster-Frey J, Pritchard DG, Donovan DM. 2009. LysK CHAP endopeptidase domain is required for lysis of live staphylococcal cells. FEMS Microbiol Lett 294:52-60. http://dx.doi.org/10.1111/j.1574-6968.2009.01541.x
125. Sulakvelidze A, Alavidze Z, Morris JG Jr. 2001. Bacteriophage therapy. Antimicrob Agents Chemother 45:649-659. http://dx.doi.org/10.1128/AAC.45.3.649-659.2001
126. Chatain-Ly MH. 2014. The factors affecting effectiveness of treatment in phages therapy. Front Microbiol 5:51. doi:10.3389/fmicb.2014 .00051.
127. Loessner MJ, Kramer K, Ebel F, Scherer S. 2002. C-terminal domains of Listeria monocytogenes bacteriophage murein hydrolases determine specific recognition and high-affinity binding to bacterial cell wall carbohydrates. Mol Microbiol 44:335-349. http://dx.doi.org/10.1046/j.1365-2958.2002.02889.x
128. Porter CJ, Schuch R, Pelzek AJ, Buckle AM, McGowan S, Wilce MCJ, Rossjohn J, Russell R, Nelson D, Fischetti VA, Whisstock JC. 2007. The 1.6 A crystal structure of the catalytic domain of PlyB, a bacteriophage lysin active against Bacillus anthracis. J Mol Biol 366:540-550. http://dx.doi.org/10.1016/j.jmb.2006.11.056
129. Schuch R, Nelson D, Fischetti VA. 2002. A bacteriolytic agent that detects and kills Bacillus anthracis. Nature 418:884-889. http://dx.doi.org/10.1038/nature01026
130. Meng X, Shi Y, Ji W, Meng X, Zhang J, Wang H, Lu C, Sun J, Yan Y. 2011. Application of a bacteriophage lysin to disrupt biofilms formed by the animal pathogen Streptococcus suis. Appl Environ Microbiol 77:8272-8279. http://dx.doi.org/10.1128/AEM.05151-11
131. Loeffler JM, Nelson D, Fischetti VA. 2001. Rapid killing of Streptococcus pneumoniae with a bacteriophage cell wall hydrolase. Science 294:2170-2172. http://dx.doi.org/10.1126/science.1066869
132. Entenza JM, Loeffler JM, Grandgirard D, Fischetti VA, Moreillon P. 2005. Therapeutic effects of bacteriophage Cpl-1 lysin against Streptococcus pneumoniae endocarditis in rats. Antimicrob Agents Chemother 49:4789-4792. http://dx.doi.org/10.1128/AAC.49.11.4789-4792.2005
133. Lood R, Winer BY, Pelzek AJ, Diez-Martinez R, Thandar M, Euler CW, Schuch R, Fischetti VA. 2015. Novel phage lysin capable of killing the multidrug-resistant Gram-negative bacterium Acinetobacter baumannii in a mouse bacteremia model. Antimicrob Agents Chemother 59:1983-1991. http://dx.doi.org/10.1128/AAC.04641-14
134. Oliveira H, Thiagarajan V, Walmagh M, Sillankorva S, Lavigne R, Neves-Petersen MT, Kluskens LD, Azeredo J. 2014. A thermostable Salmonella phage endolysin, Lys68, with broad bactericidal properties against Gram-negative pathogens in presence of weak acids. PLoS One 9:e108376. (Erratum, doi:10.1371/journal.pone.0115267.) http://dx.doi.org/10.1371/journal.pone.0108376
135. Wu H, Lu H, Huang J, Li G, Huang Q. 2012. EnzyBase: a novel database for enzybiotic studies. BMC Microbiol 12:54. http://dx.doi.org/10.1186/1471-2180-12-54
136. Zhou Y, Liang Y, Lynch KH, Dennis JJ, Wishart DS. 2011. PHAST:a fast phage search tool. Nucleic Acids Res 39:W347-W352.
137. Britton RA, Young VB. 2014. Role of the intestinal microbiota in resistance to colonization by Clostridium difficile. Gastroenterology 146:1547-1553. http://dx.doi.org/10.1053/j.gastro.2014.01.059
138. Merrigan M, Venugopal A, Mallozzi M, Roxas B, Viswanathan VK, Johnson S, Gerding DN, Vedantam G. 2010. Human hypervirulent Clostridium difficile strains exhibit increased sporulation as well as robust toxin production. J Bacteriol 192:4904-4911. http://dx.doi.org/10.1128/JB.00445-10
139. He M, Miyajima F, Roberts P, Ellison L, Pickard DJ, Martin MJ, Connor TR, Harris SR, Fairley D, Bamford KB, D'Arc S, Brazier J, Brown D, Coia JE, Douce G, Gerding D, Kim HJ, Koh TH, Kato H, Senoh M, Louie T, Michell S, Butt E, Peacock SJ, Brown NM, Riley T, Songer G, Wilcox M, Pirmohamed M, Kuijper E, Hawkey P, Wren BW, Dougan G, Parkhill J, Lawley TD. 2013. Emergence and global spread of epidemic healthcare-associated Clostridium difficile. Nat Genet 45:109-113. http://dx.doi.org/10.1038/ng.2478
140. Baines SD, O'Connor R, Freeman J, Fawley WN, Harmanus C, Mastrantonio P, Kuijper EJ, Wilcox MH. 2008. Emergence of reduced susceptibility to metronidazole in Clostridium difficile. J Antimicrob Chemother 62:1046-1052. http://dx.doi.org/10.1093/jac/dkn313
141. Freeman J, Bauer MP, Baines SD, Corver J, Fawley WN, Goorhuis B, Kuijper EJ, Wilcox MH. 2010. The changing epidemiology of Clostridium difficile infections. Clin Microbiol Rev 23:529-549. http://dx.doi.org/10.1128/CMR.00082-09
142. Cho I, Blaser MJ. 2012. The human microbiome: at the interface of health and disease. Nat Rev Genet 13:260-270.
143. Ley RE, Bäckhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI. 2005. Obesity alters gut microbial ecology. Proc Natl Acad Sci USA 102:11070-11075. http://dx.doi.org/10.1073/pnas.0504978102
144. Ridaura VK, Faith JJ, Rey FE, Cheng J, Duncan AE, Kau AL, Griffin NW, Lombard V, Henrissat B, Bain JR, Muehlbauer MJ, Ilkayeva O, Semenkovich CF, Funai K, Hayashi DK, Lyle BJ, Martini MC, Ursell LK, Clemente JC, Van Treuren W, Walters WA, Knight R, Newgard CB, Heath AC, Gordon JI. 2013. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science 341:1241214. http://dx.doi.org/10.1126/science.1241214
145. Alang N, Kelly CR. 2015. Weight gain after fecal microbiota transplantation. Open Forum Infect Dis 2:ofv004. http://dx.doi.org/10.1093/ofid/ofv004
146. Mayer MJ, Narbad A, Gasson MJ. 2008. Molecular characterization of a Clostridium difficile bacteriophage and its cloned biologically active endolysin. J Bacteriol 190:6734-6740. http://dx.doi.org/10.1128/JB.00686-08
147. Gomaa AA, Klumpe HE, Luo ML, Selle K, Barrangou R, Beisel CL. 2014. Programmable removal of bacterial strains by use of genometargeting CRISPR-Cas systems. MBio 5:e00928-13. http://dx.doi.org/10.1128/mBio.00928-13
148. Beisel CL, Gomaa AA, Barrangou R. 2014. A CRISPR design for next-generation antimicrobials. Genome Biol 15:516. http://dx.doi.org/10.1186/s13059-014-0516-x
149. Lieber MR. 2010. The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway. Annu Rev Biochem 79:181-211. http://dx.doi.org/10.1146/annurev.biochem.052308.093131
150. Paez-Espino D, Morovic W, Sun CL, Thomas BC, Ueda K, Stahl B, Barrangou R, Banfield JF. 2013. Strong bias in the bacterial CRISPR elements that confer immunity to phage. Nat Commun 4:1430. http://dx.doi.org/10.1038/ncomms2440
151. Bikard D, Euler CW, Jiang W, Nussenzweig PM, Goldberg GW, Duportet X, Fischetti VA, Marraffini LA. 2014. Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials. Nat Biotechnol 32:1146-1150. http://dx.doi.org/10.1038/nbt.3043
152. Citorik RJ, Mimee M, Lu TK. 2014. Sequence-specific antimicrobials using efficiently delivered RNA-guided nucleases. Nat Biotechnol 32:1141-1145. http://dx.doi.org/10.1038/nbt.3011
153. Nicoletti M, Bertani G. 1983. DNA fusion product of phage P2 with plasmid pBR322: a new phasmid. Mol Gen Genet 189:343-347. http://dx.doi.org/10.1007/BF00337829
154. Gibson DG, Young L, Chuang R-Y, Venter JC, Hutchison CA III, Smith HO. 2009. Enzymatic assembly of DNA molecules up to several hundred kilobases. Nat Methods 6:343-345. http://dx.doi.org/10.1038/nmeth.1318
155. de Ruyter PG, Kuipers OP, Meijer WC, de Vos WM. 1997. Foodgrade controlled lysis of Lactococcus lactis for accelerated cheese ripening. Nat Biotechnol 15:976-979. http://dx.doi.org/10.1038/nbt1097-976
156. Benbouziane B, Ribelles P, Aubry C, Martín R, Kharrat P, Riazi A, Langella P, Bermúdez-Humarán LG. 2013. Development of a stressinducible controlled expression (SICE) system in Lactococcus lactis for the production and delivery of therapeutic molecules at mucosal surfaces. J Biotechnol 168:120-129. http://dx.doi.org/10.1016/j.jbiotec.2013.04.019